Microsoft Health AI Product Strategy After the ChatGPT Health Launch

Quick Overview

A product strategy prompt for a product manager on Microsoft's health AI team after OpenAI launched ChatGPT Health. It tests picking a segment where Microsoft has a real advantage, scoping a safe and compliant first version that handles personal health data, and setting adoption and safety metrics.

Microsoft Health AI Product Strategy After the ChatGPT Health Launch

Company: Microsoft

Role: Product Manager

Category: Product Design & Strategy

Difficulty: medium

Interview Round: Other

You are a product manager on Microsoft's health AI team. OpenAI has just launched ChatGPT Health. Describe the product you would build so that Microsoft can compete: who it serves, what it does, and why people would choose it. ```hint Compete where the rival is weakest Before listing features, identify the people and the moments in their care where Microsoft is better placed than a general-purpose chat assistant, given the relationships and products Microsoft already has in healthcare. ``` ### Clarifying Questions - Should the product serve consumers managing their own health, clinicians and health systems, or the link between patients and their care teams? - Can the product build on Microsoft's existing assets, such as Copilot, Azure and its clinical documentation software, or should it stand alone? - Which country should the first version launch in, given that rules for health data and medical software differ by market? - Microsoft is also a major investor in and partner of OpenAI. Is using OpenAI's models in scope, or should the product run on Microsoft's own? ### What a Strong Answer Covers - A clear read of what the ChatGPT Health launch offers users and where it leaves gaps, rather than a feature-for-feature copy - A chosen segment and moment of need, justified by advantages Microsoft holds that OpenAI does not - A prioritized first version with a safety model: grounding in trusted clinical information, limits on diagnosis, and escalation to a clinician - Consent, privacy and regulatory handling for personal health data, including when the product could be regulated as medical software - Success metrics with safety and trust guardrails, and a route to market ### Follow-up Questions - If OpenAI copied your main feature six months after launch, what would keep users with Microsoft? - How would you decide that the assistant is safe enough to expand into a new condition or specialty? - Who should pay for this product: patients, health systems, employers or insurers? Why?

Overview: A product strategy prompt for a product manager on Microsoft's health AI team after OpenAI launched ChatGPT Health. It tests picking a segment where Microsoft has a real advantage, scoping a safe and compliant first version that handles personal health data, and setting adoption and safety metrics.

Microsoft logo
Microsoft
Oct 14, 2026
mediumProduct ManagerOtherProduct Design & Strategy
0
0

You are a product manager on Microsoft's health AI team. OpenAI has just launched ChatGPT Health. Describe the product you would build so that Microsoft can compete: who it serves, what it does, and why people would choose it.

Clarifying Questions Guidance

  • Should the product serve consumers managing their own health, clinicians and health systems, or the link between patients and their care teams?
  • Can the product build on Microsoft's existing assets, such as Copilot, Azure and its clinical documentation software, or should it stand alone?
  • Which country should the first version launch in, given that rules for health data and medical software differ by market?
  • Microsoft is also a major investor in and partner of OpenAI. Is using OpenAI's models in scope, or should the product run on Microsoft's own?

What a Strong Answer Covers Guidance

  • A clear read of what the ChatGPT Health launch offers users and where it leaves gaps, rather than a feature-for-feature copy
  • A chosen segment and moment of need, justified by advantages Microsoft holds that OpenAI does not
  • A prioritized first version with a safety model: grounding in trusted clinical information, limits on diagnosis, and escalation to a clinician
  • Consent, privacy and regulatory handling for personal health data, including when the product could be regulated as medical software
  • Success metrics with safety and trust guardrails, and a route to market

Follow-up Questions Guidance

  • If OpenAI copied your main feature six months after launch, what would keep users with Microsoft?
  • How would you decide that the assistant is safe enough to expand into a new condition or specialty?
  • Who should pay for this product: patients, health systems, employers or insurers? Why?